Objective-Systemic Lupus Erythematosus (SLE) and antiphospholipid syndrome (APS) are associated with a high prevalence of atherosclerosis. β2 glycoprotein I (β2GPI) represents a link between autoimmunity and endothelial dysfunction. Recently, β2GPI reactive T cells have been identified; however, their role in atherosclerosis is still under investigation. We evaluated early atherosclerosis in patients with SLE and APS and investigated T cell reactivity to β2GPI and its relationship with atherosclerotic process. Approach and Results-Fifty SLE, 18 patients with primary APS (PAPS), and 25 healthy controls were enrolled.
S ystemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with a multifactorial pathogenesis including genetic and environmental factors. 1, 2 The disease is characterized by the production of a wide range of autoantibodies. [3] [4] [5] [6] [7] SLE mainly affects women in their reproductive age, and any organ and system can be involved in the pathological process. 1, 8, 9 Moreover, it is well known that patients with SLE present a higher prevalence of early atherosclerosis and have a greater risk of developing cardiovascular diseases than healthy subjects. 10, 11 Increasing evidence suggests that early atherosclerosis in SLE is associated with both classical cardiovascular risk factors (hypertension, hypercholesterolemia, hypertriglyceridemia, diabetes mellitus) and disease-related risk factors. 12 Endothelial dysfunction represents the earliest stage of atherosclerosis, and the change in brachial artery flow-mediated dilatation (FMD) is a well known marker of endothelial dysfunction. 13, 14 FMD has been consistently reported to be abnormal in subjects affected by atherosclerosis or presenting cardiovascular risk factors, as well as in patients with SLE. [15] [16] [17] Measurement of the intima-media thickness (IMT) of carotid arteries by Doppler ultrasound also represents a quantitative method for detecting preclinical atherosclerosis. Increased IMT has been observed in patients with SLE with a prevalence of focal plaque up to 37% in patients with SLE without previous cardiovascular events. [18] [19] [20] In addition, the prevalence of atherosclerosis seems to be increased among patients with antiphospholipid syndrome (APS), an autoimmune disease characterized by arterial and venous thrombosis and obstetric manifestations associated with antibodies against phospholipid-protein complexes. [21] [22] [23] [24] [25] [26] Of note, the prevalence of carotid plaque has been reported to March 2014 be higher in patients with APS secondary to SLE compared with patients with primary APS (PAPS). 27 Moreover, in patients with PAPS, the titer of antiphospholipid antibodies (aPL) often represents an independent predictor of IMT. 28, 29 This may be consistent with the observation that anticardiolipin antibodies (aCL), mostly β2 glycoprotein I (β2GPI)-dependent aCL, and antiβ2GPI antibodies (aβ2GPI) are important predictors for cardiovascular events. 30, 31 β2GPI, or apolipoprotein H, is an abundant plasma glycoprotein that binds to negatively charged phospholipids and is involved in clotting mechanisms and lipid pathways. 21, 32, 33 In chronic diseases related to endothelial cell dysfunction such as SLE, APS, and atherosclerosis, β2GPI plays a role as a target antigen for an immune-mediated attack, possibly influencing the progression of disease. 21, [34] [35] [36] [37] [38] [39] β2GPI stimulates not only a vigorous adaptive humoral but also a cellular, immune response. [40] [41] [42] [43] Recently, the presence of autoreactive T cells specific for a cryptic epitope of β2GPI has been described in both patients with APS and healthy subjects. [44] [45] [46] Moreover, the frequency of these autoreactive cells was found to be significantly increased in patients with APS, suggesting that the production of aPL in patients with APS could be a result of the activation of β2GPI-reactive T cells. Recently, we showed that β2GPI is a T cell target in patients with advanced carotid atherosclerotic plaques. 47 However, the association of β2GPIreactive cells with the occurrence of atherosclerosis in patients with APS and SLE still needs to be further investigated.
The aim of this study was to evaluate the specific T cell reactivity against β2GPI in patients with SLE and PAPS and the possible association of this reactivity with markers of preclinical atherosclerosis such as endothelial dysfunction and carotid wall thickness.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Clinical Assessment
The demographic and clinical features of patients and controls are shown in Table 1 . Although not statistically significant, control subjects were slightly older than both patients with SLE and PAPS, and the disease duration was longer in patients with SLE than in those with PAPS. Cumulative glucocorticoid dosage was significantly higher in patients with SLE than in those with PAPS (P<0.0001). Overall, patients with PAPS showed higher serum levels of aPL than patients with SLE and normal controls (see Table 1 for details). Table 2 shows the distribution of traditional cardiovascular risk factors in the study population. Body mass index and systolic blood pressure were significantly higher in patients with SLE and PAPS than in controls. Diastolic blood pressure was higher in patients with SLE than in controls. Plasma levels of high-density lipoprotein (HDL)-cholesterol and Apo A-1 were significantly lower in patients with SLE and PAPS compared with controls.
Peripheral Blood Mononuclear Cell Response to β2GPI
β2GPI induced a proliferative response in peripheral blood mononuclear cell (PBMC) samples from 12 of 37 patients with SLE (32%, stimulation index [SI] ranging from 2.2-5.2) and from 3 of 12 patients with PAPS (25%, SI ranging from 3.2-4.2). No samples from healthy controls (n=23) responded to β2GPI (SLE versus controls P=0.002, PAPS versus controls P=0.034). The median SI was higher in samples from patients with SLE and PAPS than in those from healthy controls although the difference was not statistically significant ( Figure 1 ). No positive reactions were observed in cultures stimulated with human serum albumin (data not shown). No difference in T cell proliferation response was observed between patients who were taking immunosuppressants and those who were not. PBMC samples proliferating in response to β2GPI produced higher Interferon (IFN)-γ concentrations than nonproliferating samples from patients (P=0.04) and controls ( Table 3 and Figure I in the online-only Data Supplement). In contrast, no differences were observed in interleukin-4 production.
The univariate analysis demonstrated a positive correlation between SI values and IFN-γ levels (r=0.3, P=0.04) and between SI values and aβ2GPI IgM (r=0.4, P<0.0004), or aCL IgM levels (r=0.3, P<0.001) in all the enrolled subjects. The proliferative response in PBMC samples was associated with a history of arterial thrombosis and a history of thrombocytopenia and mIMT ≥0.9 (P=0.035 for the 3 parameters). In addition, a proliferative response in PBMC samples was associated with a history of anti-nuclear antibodies and anti-dsDNA serum positivity (P<0.005). No correlation was found between a proliferative response in PBMC samples and FMD.
β2GPI and TF Expression on Human Monocytes
Cytofluorimetric analysis with aβ2GPI showed a significantly higher staining for β2GPI on monocytes (% reactive cell±SD) from patients with SLE (34.2±18.9) and PAPS (36.3±22.7) compared with those from healthy controls (18.6±13.7; P=0.006 and P=0.001, respectively). Dual staining for β2GPI and TF showed a significantly higher staining on monocytes from patients with SLE (69.5±20.6) and PAPS (66.9±26.9) than from healthy controls (18.6±13.7; P=0.00001 and P=0.001, respectively). One representative example of β2GPI and TF staining on monocytes from a patient with PAPS versus a healthy control is shown in Figure 2 . Table 4 summarizes the ultrasonographic findings in patients and controls. Compared with controls, mean carotid IMT was higher in both patients with SLE and PAPS, although in PAPS the difference was not statistically significant probably because of the limited number of enrolled patients. In one 69-year-old female patient with SLE and secondary APS, an atherosclerotic plaque was detected. FMD was significantly impaired in patients with SLE (expressed both as an absolute value and as a percentage of increase from basal value) when compared with the other 2 study groups (see Table 4 for details). Nineteen patients with SLE had secondary APS (mean age comparable with that of patients with PAPS): these patients did not show a significant change in mean carotid IMT but presented a significantly reduced FMD (both absolute value and percentage of increase from basal value) when compared with patients with PAPS (Table 5 ). Univariate analysis showed that mean carotid IMT in patients with SLE was associated with systemic lupus international collaborative clinics/American College of Rheumatology damage index (SDI) (P=0.001). As reported in Table 6 , stepwise multivariate analysis confirmed SDI as an independent variable correlated with mean carotid IMT in patients with SLE. Concerning FMD (%), univariate analysis showed an inverse correlation with plasma cholesterol levels in patients with SLE (P=0.01) that was confirmed by stepwise multivariate analysis (Table 4 ). In addition, stepwise multivariate analysis showed a correlation between FMD (%) and cumulative glucocorticoid dosage (Table 4 ). Univariate analysis in patients with PAPS demonstrated that mean carotid IMT was related to age (P<0.0001), disease duration (P=0.008), systolic blood pressure (P<0.0001), diastolic blood pressure (P=0.016), plasma cholesterol levels (P=0.008), plasma triglycerides levels (P=0.001), aCL IgM (P<0.0001), and aβ2GPI IgM (P<0.0001). Only age and aβ2GPI IgM were confirmed as independent variables associated with mean carotid IMT once stepwise multivariate analysis was performed ( Table 6 ). In patients with PAPS, none of the investigated variables were demonstrated to be independently associated with FMD (%).
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IMT and FMD Correlations With Traditional and Disease-Related Risk Factors for Atherosclerosis
Anti-Apo A-I were detected in 33 of 43 (76.7%) patients with SLE, in 10 of 16 (62.5%) patients with PAPS but in none of the healthy controls (P=0.004 and P=0.001 versus controls, respectively). Moreover, median anti-Apo A-I optical density was significantly higher in patients with SLE (0.17±0.13, P<0.0001) and in patients with PAPS (0.21±0.18, P<0.0001) than in healthy controls (0.034±0.05). No significant correlation was found among anti-Apo A-I and Apo A-I plasma levels or traditional and disease-related cardiovascular risk factors.
Discussion
The main result of this study is the demonstration that a significant percentage of patients with SLE and PAPS show a β2GPI-specific T cell reactivity, which is significantly associated with IMT.
The role of β2GPI in the pathogenesis of atherosclerosis has been demonstrated in humans and in experimental models. In murine models, β2GPI was detected within early atherosclerotic lesions where it was expressed intracellularly and extracellularly. 48 β2GPI has also been detected in human atherosclerotic plaques by immunostaining studies showing that β2GPI and aβ2GPI colocalize with oxidized low-density lipoproteins (ox-LDL). 45, 49 Furthermore, immunization of Apo-E-deficient mice with β2GPI resulted in an enhancement of atherosclerosis. 50 In an experimental model of LDLreceptor-deficient mice, β2GPI-specific cellular immunity showed a central role in promoting atherogenesis. 48 When injected with lymphocytes from β2GPI-immunized animals, mice displayed fatty streaks larger than those shown in mice injected with lymphocytes from albumin-immunized controls; T-cell-depleted splenocytes were unable to promote lesion formation, thus suggesting a primary role for T-lymphocytes in mediating atherosclerosis. 48 We have recently detected β2GPI-specific T-lymphocytes in the plaque and in the peripheral blood of patients with carotid atherosclerosis. 47 In the present study, we have demonstrated the presence of a β2GPI-specific T cell reactivity in a significant percentage of patients with SLE and PAPS. In response to β2GPI, proliferating PBMC produced higher amount of IFN-γ than nonproliferating ones. By secreting proinflammatory cytokines, such as IFN-γ as well as by facilitating aPL production, β2GPI-specific T cells seem to play a pathogenic role. The reason why β2GPI-specific autoreactivity and the associated endothelial dysfunction are triggered only in a specific group of patients has still to be clarified. The antigenicity of β2GPI in patients with SLE and PAPS may be explained by the structural modifications of the protein because of chronic inflammation and oxidative stress, with the consequent generation of new antigenic epitopes. 51 Another possible explanation could be the binding of β2GPI to ox-LDL that may facilitate the presentation of β2GPI epitopes by macrophage/ dendritic cells to autoreactive T cells. 43 As a matter of fact, β2GPI and aβ2GPI have already been detected within atherosclerotic plaques, 51 and β2GPI immunization of animal models has demonstrated the role of this glycoprotein in plaque progression. 52 It is well known that proatherogenic lipid modifications generate ox-LDL, which represent the main lipoproteins within the atherosclerotic lesion; once oxidized, LDL can attract macrophages and T-lymphocytes into the arterial wall thus perpetuating atherosclerotic plaque progression. 53 Ox-LDLs have highly inflammatory and immunogenic properties. In vitro, ox-LDLs, but not native LDL, bind β2GPI and aβ2GPI autoantibodies; these immune complexes (ox-LDL/β2GPI/antibody) have been found in patients with SLE and APS where they could, at least partially, account for the accelerated atherosclerotic process. 48 It has also been shown that aβ2GPI and anti-ox-LDL/β2GPI are associated with an adverse outcome in patients with coronary artery disease. 54 Furthermore, in a previous study, aβ2GPI IgG-ox-LDL complexes have been shown to be predictive for intima-media thickness in patients with APS. 55 Other studies showed that IgG specific for β2GPI-oxLDL complexes has an important role on antigen presentation via Fcγ receptor I thus promoting the activation of β2GPI-specific T cells. 46, 56 A schematic drawing, depicting the signaling transduction pathway triggered by β2GPI/aβ2GPI on innate immune cells (leading to Th1 response and endothelial cell activation) is reported in Figure II in the online-only Data Supplement.
Table 4. Comparison of IMT and FMD in Study Populations
Increasing evidence suggests that early atherosclerosis in SLE is associated both with traditional cardiovascular risk factors and nontraditional disease-related risk factors. 12 According to previous studies, 12 we demonstrated an increase of carotid IMT and a decrease of FMD in patients with SLE, both correlating with traditional and disease-related risk factors. Compared with controls, mean carotid IMT was also found to be increased in patients with PAPS although it did not reach a statistically significant difference. These results agree with those reported in other studies on patients with PAPS where carotid IMT resulted higher than in age-and sex-matched healthy controls. 29, 57 As reported by others, 18, 19 patients with SLE showed a higher prevalence of traditional cardiovascular risk factors such as hypertension, body mass index, low HDL-cholesterol, and Apo A-1 plasma levels when compared with controls. Also patients with PAPS presented a significantly higher body mass index and systolic blood pressure and lower Apo A-1 and HDL-cholesterol than controls. 29 The suggested crossreactivity between aCL and anti-ApoA-I and anti-HDL 58 could play a role in the decreased Apo A-1 and HDL-cholesterol in patients with PAPS. However, in the present study, we did not find any correlation between anti-Apo A-I serum levels and traditional disease-related cardiovascular risk factors.
In our SLE population, SDI was the only variable to be independently related to IMT. Such a correlation has already been detected in previous studies. [59] [60] [61] Overall, these findings support the role of chronic inflammation in the atherosclerotic vascular damage.
Mean carotid IMT in patients with PAPS was comparable with that observed in patients with SLE. Multivariate analysis in our patients with PAPS showed a correlation between IMT and aβ2GPI IgM and age. This result highlighted once again the role of aPL, mainly of aβ2GPI, in the pathogenesis of atherosclerotic disease. In a previous study on patients with PAPS, aCL IgG titer had been demonstrated as an independent predictor of IMT. 62 In our cohort, FMD was significantly lower in SLE than in patients with APS and controls. Univariate analysis demonstrated that FMD inversely correlated with total triglycerides and cholesterol plasma levels, but only the latter was independently related to FMD in multivariate analysis. Direct correlation of FMD with cumulative glucocorticoid dosage has also been demonstrated in multivariate analysis, suggesting that a more aggressive therapy could prevent endothelial dysfunction in patients with SLE. The effects of the glucocorticoids on atherosclerotic process are still debated. Indeed, some authors have suggested that glucocorticoids could play a role in the development of atherosclerosis; on the contrary, glucocorticoids are undoubtedly anti-inflammatory molecules that can modulate the disease-related risk factors. 10, 18, 63 Another result of our study is that β2GPI expression and β2GPI/TF coexpression on monocyte surface were higher in patients with SLE and PAPS than in controls. This result confirms our previous data in another series of patients 42 although no correlations between β2GPI and TF expression on monocytes and FMD or IMT have been identified.
In conclusion, our study confirms increased preclinical atherosclerosis, as determined by carotid IMT and measures of endothelial function by FMD in SLE and patients with PAPS. In these populations, carotid atherosclerosis has been demonstrated to be strictly associated with chronic damage attributable to the systemic disease rather than related to traditional risk factors. In particular, the immune response to the self molecule β2GPI, the major target of aPL, may be the link between autoimmune chronic damage and endothelial dysfunction. β2GPI-specific T cells may have a pathogenic role by promoting proinflammatory conditions within the arterial wall and by sustaining the secretion of pathogenic antibodies. The evaluation of β2GPI-specific T cell response could be useful to identify patients with SLE and PAPS at high risk of cardiovascular disease development. Because this study was performed at a single center with a limited ethnic variation among the patients, extrapolation and applicability of the results to all patients with these autoimmune diseases should be carefully considered.
Early noninvasive subclinical atherosclerosis evaluation calls for further studies and suggests the need for more assessment focusing on the risk factors, preventive interventions, and therapeutic strategies.
Cardiovascular events represent one of the major causes of morbidity and mortality in patients with SLE and APS. Classical risk factors do not completely explain the excess of cardiovascular morbidity, and therefore disease-related markers of atherosclerosis are needed to identify patients at higher risk and to elaborate preventive strategies. The results of this study demonstrate the presence of a β2GPI-specific T cell reactivity in a significant percentage of patients with SLE and APS and its correlation with IMT. β2GPI-specific T cell response might represent an additional factor when evaluating the risk of atherosclerosis in patients with SLE and APS.
Significance
